Partnerships
In 2013, SomaLogic partnered with Agilent Technologies to distribute SomaScan systems to American research and educational institutions. It also signed a development deal with Quest Diagnostics to create a blood test for early-stage, non-small-cell lung cancer.[10][16] It also has partnerships with Otsuka and New England Biolabs.[17] In 2016, a study was published that used the SomaLogic system to identify nine biomarker proteins that could predict the risk of a second heart attack in those who have suffered a previous cardiovascular event.[12][18] A study in Circulation also used the 9-protein cardiovascular risk score for early detection of the harmful effects of Torcetrapib.[19] In 2016 they also developed a test to diagnose latent tuberculosis, and to predict the progression of the disease after onset.[20] In 2019, a study was published that used the SomaScan platform to build protein-based models for 11 different health indications: liver fat, kidney filtration, percentage body fat, visceral fat mass, lean body mass, cardiopulmonary fitness, physical activity, alcohol consumption, cigarette smoking, diabetes risk, and primary cardiovascular event risk.[21]
SomaLogic has a long-term partnership with the Novartis Institutes for BioMedical Research, with Novartis taking an ownership stake in SomaLogic in 2014 as a part of the extension of their initial agreement.[11] In 2016, SomaLogic formed a collaborative partnership with Oxford University,[22] and in 2017, it joined the iCarbonX Digital Life Alliance (including an investment by iCarbonX in SomaLogic).[23]
In 2018, SomaLogic teamed up with the Leeds Centre for Personalised Health and Medicine to test the SomaScan platform in clinical studies in the UK.[24] That same year, SomaLogic also began to package its insights as diagnostic information for sale to other companies, focusing on proteomic data.[25] In 2019, SomaLogic entered into a new 10-year agreement with Novartis to use the SomaScan proteomics technology in drug discovery and development efforts.[26] Also that year, SomaLogic began commercially offering health information tests on the SomaScan Platform to prescribing physicians in Colorado.[27] In 2020, NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, launched a new company, FonesLife Corporation, that will collaborate with SomaLogic to bring proteomic-based health monitoring tests to people in Japan.[28]
